Inventiva

When a 110% Price Gap Turns Into a Trading Halt Nightmare: The Inventiva S.A. ADR Story ($IVA)

A 70% gain in two weeks should feel like victory. Instead, it exposed one of the most dangerous traps in biotech investing, and a lesson every ADR trader needs to know.

Inventiva

Why a French Biotech Nobody's Heard Of Could Deliver 5x Returns in 2026

First and only to hit both FDA surrogate endpoints in Phase 2b. Fully enrolled Phase 3, topline H2 2026. Most advanced oral MASH program outside approved Rezdiffra. Yet trading at $650M—1/6th~1/15th of comparable competitors.